Quantcast
Last updated on April 16, 2014 at 5:23 EDT

Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol”

June 18, 2013

The patent covers the process and preparation of Tapentadol for the treatment of moderate to severe-acute pain

NESS ZIONA, Israel, June 18, 2013 /PRNewswire/ –

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients
(APIs), generic and innovative intermediates, and finished dosage forms based on selected
drug delivery systems, announced today that the company has been granted a United States
patent for Tapentadol. Tapentadol is indicated in the US and Europe for the oral treatment
of moderate-to-severe acute pain.

US Patent number 8,410,176 B2 is titled Intermediate Compounds and Processes for the
Preparation of Tapentadol and Related Compounds. Mapi’s innovative process enables the
company to obtain Tapentadol in an optically active pure form. The process is cost
effective, uses easily available reagents and fits scalable industrial processes.

Tapentadol is indicated for the relief of moderate-to-severe acute pain. This segment
of pain relievers has continuously grown during the last decade as a result of improved
delivery technologies, increased physician recognition of the need for effective pain
treatment, and the rising requirement for pain medication by the growing ageing
population.

“The patent acceptance announced today is Mapi’s second in just one month. The first
[http://www.mapi-pharma.com/news/?pid=30 ] was for a long acting depot formulation of
Glatiramer Acetate for the treatment of MS. Both patents strengthen Mapi’s patent
position, support the business plan and advance the company one step closer to bringing
patients improved medications at affordable prices,” said Mapi Pharma President & CEO Mr.
Ehud Marom. “The pain relief market requires a specific expertise in dealing with potent
pharmaceuticals. Mapi is uniquely positioned to answer the growing needs of this market.”

The moderate-to-severe acute pain relief market is a growing therapeutic area. It is
currently estimated at about US $10 billion and is expected to continue expanding for the
foreseeable future.

About Mapi-Pharma

Mapi Pharma (Mapi) is an international pharmaceutical company specializing in complex
bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high
development barrier generics and novel finished dosage forms based on selected drug
delivery systems. Mapi is focused on developing innovative delivery systems for
pharmaceuticals such as long acting depot injections. Mapi has an extensive pipeline of
medications that will follow the FDA regulatory pathway 505(b)(2). The company is built on
the strong chemical and pharmaceutical R&D capabilities of its founders, a deep
understanding of the global market and of regulatory needs and its ability to foster local
cooperation and enduring relationships in all of the countries in which it is present.
Mapi is dedicated to providing generic and innovative intermediates & APIs as well as
developing finished dosage forms – either to Mapi’s internal API program, as a vertically
integrated company, or generically, to other leading brands. Mapi is headquartered in
Israel. It has R&D facilities in Israel, China and Germany and is currently building an
API manufacturing site in Neot Hovav, Israel’s designated chemical park. The company has a
strong IP position, filing more than 20 patent applications for APIs and formulations in
less than three years since it began operations. For more information:

http://www.mapi-pharma.com

        Press Contact:
        Marjie Hadad
        Media Liaison
        Mapi Pharma
        marjie@mapi-pharma.com
        +972-54-536-5220

SOURCE Mapi Pharma Ltd


Source: PR Newswire